KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Receivables (2016 - 2025)

Eli Lilly's Receivables history spans 17 years, with the latest figure at $20.2 billion for Q4 2025.

  • For Q4 2025, Receivables rose 51.82% year-over-year to $20.2 billion; the TTM value through Dec 2025 reached $20.2 billion, up 51.82%, while the annual FY2025 figure was $20.2 billion, 51.82% up from the prior year.
  • Receivables reached $20.2 billion in Q4 2025 per LLY's latest filing, up from $19.5 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $20.2 billion in Q4 2025 to a low of $6.7 billion in Q1 2021.
  • Average Receivables over 5 years is $11.0 billion, with a median of $9.6 billion recorded in 2023.
  • Peak YoY movement for Receivables: grew 4.82% in 2021, then skyrocketed 61.45% in 2025.
  • A 5-year view of Receivables shows it stood at $8.1 billion in 2021, then increased by 5.31% to $8.6 billion in 2022, then skyrocketed by 32.45% to $11.3 billion in 2023, then increased by 17.11% to $13.3 billion in 2024, then surged by 51.82% to $20.2 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Receivables are $20.2 billion (Q4 2025), $19.5 billion (Q3 2025), and $17.2 billion (Q2 2025).